Vector Borne Diseases: Clinical Trials

297 trials for Vector Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

297 completed. 297 Phase 3, 47 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3297Completed 297
Phase 247Completed 47

Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases

Trials (filtered) newest first · largest first

All 297 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Single Arm, Open Study on vYF in Adults
Yellow fever vaccine (live) - Yellow Fever
Phase 3CompletedSanofi Pasteur, a Sanofi Company2542025-10-232026-02-03
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
Yellow fever vaccine (live), YF vaccine (live) - Yellow Fever Immunization
Phase 3CompletedSanofi6402025-05-222026-02-02
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
TDV, Placebo - Dengue Fever
Phase 2 / Phase 3CompletedTakeda1872025-01-312025-12-30
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever
Phase 3CompletedKhyber Medical University Peshawar2842024-12-172025-06-26
Parasite Clearance and Protection From Infection (PCPI) in Zambia
SP (Macleods Pharmaceuticals Ltd), AS (Guilin Pharmaceuticals) - Malaria
Phase 3CompletedLondon School of Hygiene and Tropical Medicine6002024-07-242025-03-12
Parasite Clearance and Protection From Infection (PCPI) in Cameroon
SP (Macleods Pharmaceuticals Ltd), SPAQ (Guilin Pharmaceuticals), AS (Guilin Pharmaceuticals) - Malaria
Phase 3CompletedLondon School of Hygiene and Tropical Medicine9022024-06-102025-03-12
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
KLU156, Coartem - Uncomplicated Plasmodium Falciparum Malaria
Phase 3CompletedNovartis Pharmaceuticals17202024-03-072026-11-04
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial
Carica Papaya Leaf Extract, Placebo - Dengue
Phase 3CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh2502023-10-012026-06-16
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
Mesh - spatial repellent impregnated with transfluthrin (2500mg), Information and Education Campaigns (IEC), test and treat malaria cases - Malaria, Childhood ALL
Phase 3CompletedThe Mentor Initiative24002023-06-052024-04-23
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
STAMARIL, SII-YFV - Yellow Fever
Phase 3CompletedSerum Institute of India Pvt. Ltd.18242023-05-112025-05-07
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine - Uncomplicated Plasmodium Falciparum Malaria
Phase 2 / Phase 3CompletedMuhimbili University of Health and Allied Sciences3842023-05-012026-09-23
Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
VLA15, Normal Saline - Lyme Disease
Phase 3CompletedPfizer35472022-12-122026-05-07
Randomised Clinical Trial in Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan
drug: miltefosine with thermotherapy - Old World Cutaneous Leishmaniasis
Phase 3CompletedMedecins Sans Frontieres, Netherlands6452022-10-072026-07-30
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
VLA15, Saline - Lyme Disease
Phase 3CompletedPfizer125462022-08-042026-06-04
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Acoziborole - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Phase 2 / Phase 3CompletedDrugs for Neglected Diseases352022-07-092026-04-06
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
CHIKV VLP/adjuvant, Placebo - Chikungunya Virus
Phase 3CompletedBavarian Nordic4132022-05-122024-12-13
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)
Albendazole Pill, Ivermectin Pill, Ivermectin Injectable Product - Malaria
Phase 3CompletedBarcelona Institute for Global Health481452022-03-172025-03-14
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
Active, Placebo - Chikungunya
Phase 3CompletedButantan Institute7542022-02-142026-06-04
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Acoziborole, Placebo - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Phase 2 / Phase 3CompletedDrugs for Neglected Diseases12082021-12-302025-03-20
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
CHIKV VLP/adjuvant, Placebo - Chikungunya Virus
Phase 3CompletedBavarian Nordic32582021-09-292024-08-30

Showing 20 of 297. Sign in to see all of them.

Narrower conditions

Malaria (133)  ·  Malaria, Falciparum (47)  ·  Encephalitis, Japanese (30)  ·  Dengue (18)  ·  Leishmaniasis, Cutaneous (14)  ·  Malaria, Vivax (14)  ·  Leishmaniasis, Visceral (13)  ·  Severe Dengue (10)  ·  Encephalitis, Tick-Borne (9)  ·  Anemia (8)  ·  Schistosomiasis (8)  ·  Trypanosomiasis, African (7)  ·  Chagas Disease (6)  ·  Elephantiasis, Filarial (6)  ·  HIV Infections (6)

Broader conditions

Infections (292)  ·  Mosquito-Borne Diseases (222)  ·  Parasitic Diseases (216)  ·  Protozoan Infections (199)  ·  Virus Diseases (77)  ·  RNA Virus Infections (76)  ·  Arbovirus Infections (67)  ·  Flaviviridae Infections (62)  ·  Flavivirus Infections (61)  ·  Central Nervous System Diseases (43)  ·  Central Nervous System Infections (43)  ·  Euglenozoa Infections (42)  ·  Nervous System Diseases (42)  ·  Neuroinflammatory Diseases (40)

Interventions

Artemether, Lumefantrine Drug Combination (33)  ·  fanasil, pyrimethamine drug combination (31)  ·  Chloroquine (22)  ·  Artesunate (18)  ·  Amodiaquine (16)  ·  Primaquine (16)  ·  Azithromycin (11)  ·  amodiaquine, artesunate drug combination (11)  ·  miltefosine (11)  ·  Paromomycin (10)  ·  Praziquantel (10)  ·  pyronaridine tetraphosphate, artesunate drug combination (9)  ·  Doxycycline (8)  ·  Ivermectin (8)  ·  Mefloquine (7)

Sponsors

London School of Hygiene and Tropical Medicine (43)  ·  Sanofi Pasteur, a Sanofi Company (16)  ·  Drugs for Neglected Diseases (14)  ·  Pfizer (14)  ·  University of Oxford (13)  ·  Valneva Austria GmbH (13)  ·  GlaxoSmithKline (10)  ·  University of California, San Francisco (9)  ·  Institute of Tropical Medicine, Belgium (8)  ·  Takeda (7)  ·  Sanofi (6)  ·  Liverpool School of Tropical Medicine (5)  ·  Medicines for Malaria Venture (5)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (5)  ·  Menzies School of Health Research (4)

Countries

Kenya (29)  ·  Burkina Faso (28)  ·  Uganda (27)  ·  United States (23)  ·  Ghana (18)  ·  Mali (16)  ·  Tanzania (16)  ·  Democratic Republic of the Congo (15)  ·  Brazil (14)  ·  Thailand (14)  ·  The Gambia (12)  ·  India (11)  ·  Colombia (9)  ·  Mozambique (9)  ·  Nigeria (9)

Top investigators

Grant Dorsey, MD, PhD (6)  ·  Diane V Havlir, MD (4)  ·  Astrid Kaltenboeck, Ph.D. (3)  ·  Brian Greenwood, FRCP, FRS (3)  ·  Brian Greenwood, MD (3)  ·  Eric Ottesen, MD (3)  ·  Jayaram Menon, MBBS (3)  ·  Paul J Milligan, PhD (3)  ·  Shyam Sundar, MD (3)  ·  Tsin Yeo, MBBS (3)  ·  Alassane Dicko, Professor (2)

Results publications

PMID 40099800, PMID 23433102, PMID 26666916, PMID 39324693, PMID 11873261, PMID 22610930, PMID 32228663, PMID 10656038, PMID 20934459, PMID 21849081, PMID 22993389, PMID 25425434, PMID 26214039, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28871961, PMID 29300876, PMID 29547881, PMID 29897841, PMID 33020153, PMID 33212068, PMID 33822015, PMID 34003796, PMID 34219653, PMID 35659904, PMID 35709798, PMID 35732155, PMID 36534705, PMID 8937280, PMID 9790423, PMID 12510893, PMID 16235350, PMID 16503464, PMID 16551365, PMID 16640611, PMID 16702588, PMID 16837678, PMID 17046467, PMID 17239256, PMID 17519409, PMID 17519410, PMID 17582067, PMID 17940319, PMID 17971864, PMID 18074034, PMID 18171245, PMID 18213379, PMID 18237394, PMID 18394765

NIH funding

2008 (2), 2014 (2), 2019 (2), 2023 (2), P01HD059454 (2), 2009 (1), 2015 (1), 2016 (1), 2018 (1), 2025 (1), P60AR036308 (1), R01AI031561 (1), R01AI104702 (1), U01AI126610 (1), U01AI138910 (1)